Overview

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Status:
Completed

Trial end date:
2018-04-05

Target enrollment:

Participant gender:

Summary

A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Evolocumab